Legend Biotech Corp
NASDAQ:LEGN
Intrinsic Value
Legend Biotech Corp. is a holding company, which engages in the discovery and development of novel cell therapies for oncology and other indications. [ Read More ]
The intrinsic value of one LEGN stock under the Base Case scenario is 52.93 USD. Compared to the current market price of 56.93 USD, Legend Biotech Corp is Overvalued by 7%.
Valuation Backtest
Legend Biotech Corp
Run backtest to discover the historical profit from buying and selling LEGN stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Legend Biotech Showcases Strong CARVYKTI Sales
2023-Q4 Earnings Call
Legend Biotech celebrates a landmark year as their leading CAR-T therapy, CARVYKTI, secures positive opinions for expansion in Europe and is set for an extended launch in the US. The therapy achieved a rapid market foothold with $0.5 billion in sales. For Q4 2023 alone, sales surged to $159 million, propelled by manufacturing efficiency and market share gains. The company's solid financial position, with a cash reserve of $1.3 billion, underscores the potential for sustained growth and investment in production, committing to a supply target of 10,000 patients by 2025. Revenue is up 189% year-over-year, but net losses increased slightly, from $446.3 million in 2022 to $518.3 million in 2023. Legend remains on track with its finances and is strategically poised for expansion and scale, planning further capacity increases for CARVYKTI and initiating trials in other cancers, all while projecting a financial runway through 2025.
Balance Sheet Decomposition
Legend Biotech Corp
Current Assets | 1.5B |
Cash & Short-Term Investments | 1.3B |
Receivables | 100m |
Other Current Assets | 88.7m |
Non-Current Assets | 350.8m |
PP&E | 189.2m |
Intangibles | 4.1m |
Other Non-Current Assets | 157.5m |
Current Liabilities | 216.4m |
Accounts Payable | 153m |
Other Current Liabilities | 63.5m |
Non-Current Liabilities | 380.8m |
Long-Term Debt | 325.5m |
Other Non-Current Liabilities | 55.3m |
Earnings Waterfall
Legend Biotech Corp
Revenue
|
285.1m
USD
|
Cost of Revenue
|
-144.2m
USD
|
Gross Profit
|
140.9m
USD
|
Operating Expenses
|
-583.1m
USD
|
Operating Income
|
-442.2m
USD
|
Other Expenses
|
-76m
USD
|
Net Income
|
-518.3m
USD
|
Free Cash Flow Analysis
Legend Biotech Corp
What is Free Cash Flow?
LEGN Profitability Score
Profitability Due Diligence
Legend Biotech Corp's profitability score is 30/100. The higher the profitability score, the more profitable the company is.
Score
Legend Biotech Corp's profitability score is 30/100. The higher the profitability score, the more profitable the company is.
LEGN Solvency Score
Solvency Due Diligence
Legend Biotech Corp's solvency score is 72/100. The higher the solvency score, the more solvent the company is.
Score
Legend Biotech Corp's solvency score is 72/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
LEGN Price Targets Summary
Legend Biotech Corp
According to Wall Street analysts, the average 1-year price target for LEGN is 88.01 USD with a low forecast of 65.65 USD and a high forecast of 105 USD.
Shareholder Return
LEGN Price
Legend Biotech Corp
Average Annual Return | 16.29% |
Standard Deviation of Annual Returns | 50.01% |
Max Drawdown | -45% |
Market Capitalization | 10.4B USD |
Shares Outstanding | 182 288 400 |
Percentage of Shares Shorted | 10.8% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Legend Biotech Corp. is a holding company, which engages in the discovery and development of novel cell therapies for oncology and other indications. The company is headquartered in Somerset, New Jersey and currently employs 1,071 full-time employees. The company went IPO on 2020-06-04. is a clinical-stage biopharmaceutical company. The firm is engaged in the discovery and development of cell therapies for oncology and other indications. Its lead product candidate, LCAR- B38M (cilta-cel), is an autologous CAR-T cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in a number of hematologic malignancies, including multiple myeloma (MM). The firm have a portfolio of earlier-stage autologous product candidates targeting various cancers, including Non-Hodgkins Lymphoma (NHL), Acute Myeloid Leukemia (AML), and T cell Lymphoma (TCL). The firm is also developing allogeneic CAR-T product candidates targeting CD20 for the treatment of NHL. The company also has product candidates in early preclinical and clinical development for the treatment of solid tumors as well as infectious diseases.
Contact
IPO
Employees
Officers
The intrinsic value of one LEGN stock under the Base Case scenario is 52.93 USD.
Compared to the current market price of 56.93 USD, Legend Biotech Corp is Overvalued by 7%.